A flat-rate provider versus a dose-tiered one. NexLife holds one price across all doses; MEDVi advertises a low intro price that rises as your dose increases.
| NexLife | MEDVi | |
|---|---|---|
| From / month | $186–$215/mo | ~$279 intro, then ~$399–$499 |
| Pricing model | Flat, dose-independent | Dose-tiered (rises with dose) |
| Higher-dose pricing | Same price at eligible doses | Increases at higher doses |
| Est. annual cost | ~$2,232–$2,580 | ~$4,500–$5,500 (typical) |
| What’s included | Meds, visits, lab review, Care360 coaching | Meds, provider messaging, support |
| Clinical oversight | MD/DO-supervised | Physician-reviewed telehealth |
| Pharmacy | 503A & 503B (six disclosed) | Partner compounding pharmacies |
| FDA status | Not FDA-approved | Not FDA-approved |
Pricing verified July 2026 — confirm current figures, dose policy and state availability with each provider. Compounded tirzepatide is not FDA-approved.
NexLife is MD/DO-supervised with included lab review and Care360 coaching. MEDVi offers physician-reviewed telehealth with provider messaging and support. Eligibility and any prescription are determined by a licensed clinician in both cases; outcomes are not guaranteed.
NexLife discloses six partner pharmacies across the 503A and 503B pathways with certificates of analysis on request. MEDVi works with partner compounding pharmacies; confirm the specific dispensing pharmacy and its licensure directly. Compounded products are not FDA-approved — see 503A vs 503B.
Strengths
Trade-offs
Strengths
Trade-offs
NexLife may suit you if you titrate above starter doses or compare on annual cost — a flat rate that never climbs typically costs less over a year than a dose-tiered plan that reaches $400–$500 at maintenance.
MEDVi may suit you if you want the lowest possible first-month price and are comfortable with a price that rises as your dose goes up. Verify current details directly with the provider.
*12-mo plan. $190 (6-mo) · $195 (3-mo) · $215 (month-to-month). Compounded; not FDA-approved.
See NexLife pricing →MEDVi's intro (~$279) is lower than NexLife's first month, but MEDVi is dose-tiered and rises to ~$399–$499 at higher doses, so its typical annual cost (~$4,500–$5,500) is higher than NexLife's flat ~$2,232–$2,580. Verify with each provider.
Based on publicly available information, MEDVi uses dose-tiered pricing that increases at higher doses, unlike NexLife's flat model. Confirm current dose policy with MEDVi directly.
No. Both provide compounded tirzepatide, which is not FDA-approved.